About this item:

131 Views | 134 Downloads

Author Notes:

Address correspondence to H. Shim hshim@emory.edu

H. Shim and L. Wei contributed equally to this work.

We thank J. Scott Cordova, Scott Hwang, Ian Crocker, Eduard Schreibmann, Hui-Kuo G. Shu, Daniel Brat, Zhongxing Liang, and the brain tumor patient management team at Winship Cancer Institute for their support throughout this project.

We thank Andrew Maudsley and Sulaiman Sheriff for providing us with 3D-ESPI MRSI sequence and MIDAS software.

Subjects:

Research Funding:

This work was supported by National Institutes of Health grants NIH/NCI R21 CA141836 and NIH/NCI U01 CA172027.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Radiology, Nuclear Medicine & Medical Imaging
  • epigenetic modification
  • glioblastoma histone deacetylase (HDAC)
  • MR spectroscopic imaging
  • vorinostat
  • POSITRON EMISSION TOMOGRAPHY
  • HUMAN BRAIN-TUMORS
  • ADJUVANT TEMOZOLOMIDE
  • TRUE PROGRESSION
  • PSEUDOPROGRESSION
  • PATTERNS
  • RADIOTHERAPY
  • CONCOMITANT
  • GLIOMA
  • MULTIFORME

Use of High-Resolution Volumetric MR Spectroscopic Imaging in Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor

Tools:

Journal Title:

American Journal of Roentgenology

Volume:

Volume 203, Number 2

Publisher:

, Pages W158-W165

Type of Work:

Article | Post-print: After Peer Review

Abstract:

OBJECTIVE. Improved predictive imaging would enable personalization and adjustment of treatment, which are critical for patients with glioblastomain whom therapy is likely to fail. This article describes the use of MR spectroscopic imaging (MRSI) to predict early clinical and behavioral response to a therapy and an effort to develop high-resolution, volumetric MRSI to improve its clinical application. CONCLUSION. MRSI may enable quantitative analysis of brain tumor response, offering a precise tool for monitoring of patients in clinical trials.

Copyright information:

© American Roentgen Ray Society.

Export to EndNote